

**Baxter International Inc.**  
**Key Product Line Sales**  
**Periods Ending December 31, 2006 and 2005**  
**(unaudited)**  
**(\$ in millions)**

	Q4 2006	Q4 2005 <sup>1</sup>	% Growth @ Actual Rates	% Growth @ Constant Rates	YTD 2006	YTD 2005 <sup>1</sup>	% Growth @ Actual Rates	% Growth @ Constant Rates
<b>BioScience</b>								
Recombinants	\$452	\$394	15%	11%	\$1,696	\$1,527	11%	11%
Plasma Proteins <sup>2</sup>	262	193	36%	33%	881	709	24%	24%
Antibody Therapy	207	147	41%	38%	785	452	74%	73%
BioSurgery <sup>3</sup>	78	67	16%	13%	298	266	12%	12%
Transfusion Therapies	145	140	4%	2%	516	547	(6%)	(5%)
Other <sup>4</sup>	43	69	(38%)	(42%)	220	351	(37%)	(37%)
<b>Total BioScience</b>	<b>\$1,187</b>	<b>\$1,010</b>	<b>18%</b>	<b>14%</b>	<b>\$4,396</b>	<b>\$3,852</b>	<b>14%</b>	<b>14%</b>
<b>Medication Delivery</b>								
IV Therapies <sup>5</sup>	\$341	\$316	8%	6%	\$1,285	\$1,225	5%	5%
Drug Delivery	219	196	12%	11%	832	818	2%	1%
Infusion Systems	221	194	14%	12%	817	853	(4%)	(5%)
Anesthesia and Injectable Drugs	247	249	(1%)	(2%)	938	1,021	(8%)	(8%)
Other <sup>6</sup>	11	17	(35%)	(29%)	45	73	(38%)	(36%)
<b>Total Medication Delivery</b>	<b>\$1,039</b>	<b>\$972</b>	<b>7%</b>	<b>5%</b>	<b>\$3,917</b>	<b>\$3,990</b>	<b>(2%)</b>	<b>(2%)</b>
<b>Renal</b>								
PD Therapy	\$429	\$400	7%	6%	\$1,634	\$1,553	5%	6%
HD Therapy	108	109	(1%)	(2%)	431	454	(5%)	(5%)
<b>Total Renal<sup>7</sup></b>	<b>\$537</b>	<b>\$509</b>	<b>6%</b>	<b>4%</b>	<b>\$2,065</b>	<b>\$2,007</b>	<b>3%</b>	<b>3%</b>
<b>TOTAL BAXTER</b>	<b>\$2,763</b>	<b>\$2,491</b>	<b>11%</b>	<b>9%</b>	<b>\$10,378</b>	<b>\$9,849</b>	<b>5%</b>	<b>5%</b>

<sup>1</sup> Prior year sales data has been reclassified to reflect the changes that are described in notes 2, 3, 4 and 7 below.

<sup>2</sup> Includes plasma-derived hemophilia (FVII, FVIII, FIX and FEIBA), albumin, and certain other plasma-based products. Sales of Tisseel, sales of plasma to third parties, and contract manufacturing revenues were previously reported in Plasma Proteins, and are now reported in other product lines, as detailed below.

<sup>3</sup> Includes sales of Tisseel and FloSeal/CoSeal, which were previously reported in Plasma Proteins and Other, respectively.

<sup>4</sup> Principally includes vaccines and sales of plasma to third parties. The sales of plasma to third parties were previously reported in Plasma Proteins. The prior year sales include contract manufacturing revenues.

<sup>5</sup> Principally includes intravenous solutions and nutritional products.

<sup>6</sup> Principally includes other hospital-distributed products.

<sup>7</sup> Sales of pharmaceutical and certain other products, which were previously reported in Other, are now reported in PD Therapy.